BIO 2026: Five Industry Shifts That Will Shape Clinical Development Over the Next Few Years

By Nicole Brenna, US Business Development Director, Cromos Pharma

Every BIO International Convention has its own defining conversation. Some years it’s financing, others it’s a new therapeutic modality or regulatory change.

BIO 2026 felt different.

After four days of meetings with biotech companies, pharmaceutical sponsors, investors, CROs, and technology providers, I kept hearing the same questions:

How do we expand globally? How do we move faster? And how do we reduce development risk without slowing innovation?

Looking back, five clear industry shifts stood out.

1. Global competition is reshaping clinical development

One of the strongest themes throughout BIO 2026 was that competitive advantage is no longer determined by scientific innovation alone. Increasingly, it depends on how efficiently companies can translate innovation into clinical development through faster trial execution, supportive regulatory environments, and globally relevant evidence generation.

This shift is changing how sponsors design development programs. Rather than focusing on individual markets, companies are building globally integrated strategies from the outset, while cross-border partnering and licensing activity continue to accelerate.

For sponsors, the implication is clear: successful clinical development increasingly depends not only on the strength of the science, but also on the ability to execute efficiently across multiple regions.

2. China has become a global innovation leader

China’s role in biopharma was one of the defining conversations at BIO 2026. For years, Chinese biotech was framed around cost and manufacturing capacity. That framing is over. China-originated assets, particularly in oncology (ADCs and bispecifics), immunology, and metabolic disease, are now driving some of the largest licensing deals in the industry’s history, and Western pharma is treating them as core strategic pipelines rather than opportunistic bolt-ons.

This shift is reflected in industry data. According to GlobalData, more than 60% of biopharma professionals now view Chinese biotech as either a competitive threat or both a partner and competitor.

For sponsors, the message is clear: China is no longer simply a market for clinical research, it has become a major source of innovation, making a global development strategy more important than ever.

3. The FDA Is Focused on Making Clinical Development More Efficient

The FDA Town Hall was one of the most anticipated sessions at BIO 2026. Agency leadership acknowledged recent operational challenges but focused primarily on what comes next: making drug development more efficient without compromising scientific standards.

The centerpiece of that effort is Operation Trailblazer, a new HHS initiative designed to modernize early clinical development. Among the proposed changes are faster IND pathways, clearer guidance for sponsors, and new tools to support early-stage development.

The message from the FDA was clear. The goal is not to lower the bar for approval, but to reduce unnecessary complexity, improve predictability, and help innovative therapies reach patients faster. For sponsors, this reinforces the importance of designing development programs with regulatory strategy in mind from the very beginning.

4. AI in drug discovery has moved from promise to proof

Artificial intelligence remained one of the defining themes at BIO 2026, but the conversation has fundamentally changed. Just a few years ago, the question was whether AI could improve drug discovery. This year, the focus shifted to clinical results.

Several AI-enabled platforms, including Insilico Medicine, Xaira Therapeutics, Generate Biomedicines, Isomorphic Labs, are now advancing molecules through clinical development. As a result, investors and partners are increasingly evaluating these technologies based on clinical data rather than computational promise.

At the same time, AI is expanding beyond drug discovery into protocol design, trial optimization, and data analysis, becoming an integral part of the clinical development process rather than a standalone discovery tool.

5. Innovation is shifting toward large-population diseases

Another trend that stood out at BIO 2026 was the growing focus on diseases affecting large patient populations. While rare diseases and precision therapies remain important, much of the industry’s momentum is now centered on cardiometabolic disease, obesity, inflammation, and Alzheimer’s disease.

This shift reflects changing R&D priorities. As scientific confidence in these areas has grown and breakthrough therapies have demonstrated commercial and clinical success, sponsors are increasingly investing in programs that address both significant unmet needs and large global populations. Clinical development strategies are evolving accordingly, with greater emphasis on scalable trial designs, broader patient recruitment, and global evidence generation.

What I’m Taking Back from BIO 2026

BIO 2026 reinforced something I see more and more in conversations with sponsors: strong science is only the starting point.

The companies best positioned to succeed are those thinking early about global strategy, regulatory expectations, operational risk, and the partners they need to move efficiently across regions.

That is what made this year’s conversations so valuable. They were less about ambition in the abstract and more about practical readiness: how to design smarter programs, avoid preventable delays, and build development strategies that can hold up in a more competitive global market.

For me, the biggest takeaway is simple: the next phase of biotech will be shaped not only by innovation, but by the ability to execute that innovation globally.